Table 2.
Variables and correction outcomes of patients with water diuresis
| Baseline Date | After Water Diuresis Manifestation | Correction Methods for the Next 6 h from s[Na]aft Measurement | 6 h after s[Na]aft Measurement | s[Na] Change | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient No. | Age (yr) | Sex | s[Na]aft Measurement Time from Water Diuresis Manifestation (h) | s[Na]aft (mEq/L) | UVwd (ml/h) | u[Na+K]wd (mEq/L) | EFWCaft (ml/h) | s[Na]aft+6h (mEq/L) | UVaft+6h (ml/h) | u[Na+K]aft+6h (mEq/L) | EFWCaft+6h (ml/h) | 24 h | 48 h | |
| 1 | 65 | Female | 1 | 123 | 180 | 14.7 | 158 | DDAVP, D5W | 122 | 12 | 53.9 | 7 | 9 | 15 |
| 2 | 70 | Female | 2 | 121 | 113 | 34.9 | 80 | DDAVP, D5W | 117 | 29 | 101.2 | 4 | 6 | 10 |
| 3 | 82 | Male | 6 | 119 | 243 | 8.5 | 226 | D5W | 116 | 50 | 31.4 | 36 | 9 | 15 |
| 4 | 43 | Male | 2 | 106 | 220 | 13.7 | 192 | D5W | 110 | 135 | 14.2 | 118 | 9 | 15 |
| 5 | 92 | Female | 1 | 112 | 640 | 46.5 | 374 | DDAVP, D5W | 114 | 110 | 99.9 | 14 | 4 | 5 |
| 6 | 54 | Male | 1 | 112 | 520 | 10.1 | 473 | D5W | 113 | 300 | 7.7 | 280 | 6 | 10 |
| 7 | 61 | Male | 6 | 122 | 450 | 31.8 | 333 | D5W | 121 | 44 | 93.2 | 10 | 7 | 13 |
| 8 | 87 | Female | 4 | 119 | 220 | 13.9 | 194 | D5W | 123 | 83 | 137.7 | −10 | 10 | 12 |
| 9 | 55 | Female | 1 | 133 | 217 | 36.6 | 157 | DDAVP, D5W | 127 | 80 | 139.6 | −8 | 10 | 16 |
| 10 | 93 | Female | 5 | 124 | 370 | 19.6 | 312 | DDAVP, D5W | 115 | 73 | 88.2 | 17 | 0 | 3 |
| 11 | 51 | Male | 1 | 119 | 100 | 22.2 | 81 | D5W | 121 | 93 | 71.2 | 38 | 10 | 14 |
| 12 | 53 | Male | 12 | 135 | 300 | 20.5 | 254 | D5W | 134 | 155 | 39 | 110 | 17 | 19 |
| 13 | 51 | Male | 4 | 116 | 379 | 15.1 | 330 | D5W | 116 | 117 | 9.8 | 107 | 10 | 8 |
| 14 | 71 | Female | 1 | 117 | 400 | 15.5 | 347 | DDAVP, D5W | 114 | 160 | 36.8 | 108 | 10 | 12 |
| 15 | 74 | Male | 1 | 116 | 230 | 39.1 | 152 | NS | 120 | 90 | 34.3 | 64 | 6 | 9 |
| 16 | 49 | Female | 1 | 123 | 150 | 10.1 | 138 | DDAVP, D5W | 122 | 38 | 13 | 34 | 8 | 17 |
| 17 | 66 | Male | 1 | 116 | 120 | 30.9 | 88 | D5W | 114 | 14 | 34.9 | 10 | 5 | 9 |
| 18 | 49 | Female | 2 | 121 | 117 | 24.3 | 94 | D5W | 121 | 47 | 45.3 | 29 | 6 | 15 |
| 19 | 84 | Female | 2 | 126 | 250 | 29.5 | 191 | DDAVP, D5W | 123 | 43 | 113.6 | 3 | 8 | 9 |
| 20 | 73 | Male | 2 | 122 | 115 | 32 | 85 | D5W | 123 | 63 | 32 | 47 | 6 | 9 |
| 21 | 70 | Female | 6 | 124 | 100 | 16.7 | 87 | D5W | 126 | 50 | 33.8 | 37 | 5 | 14 |
| 22 | 47 | Male | 1 | 107 | 660 | 42.3 | 399 | DDAVP, D5W | 105 | 399 | 42.3 | 238 | 5 | 8 |
| 23 | 71 | Male | 1 | 113 | 700 | 46.6 | 411 | DDAVP, D5W | 114 | 40 | 29.4 | 30 | 8 | 10 |
| 24 | 97 | Female | 2 | 116 | 250 | 30.9 | 183 | DDAVP, D5W | 113 | 77 | 170.3 | −39 | 6 | 12 |
| 25 | 74 | Female | 1 | 117 | 320 | 31.7 | 233 | DDAVP, D5W | 118 | 70 | 65.7 | 31 | 9 | 18 |
| 26 | 80 | Female | 2 | 118 | 240 | 21.9 | 195 | DDAVP, D5W | 119 | 50 | 50.7 | 29 | 5 | 12 |
| 27 | 79 | Male | 2 | 119 | 133 | 49.3 | 78 | D5W | 115 | 70 | 80.3 | 21 | 6 | 13 |
| 28 | 84 | Female | 2 | 120 | 100 | 32.2 | 73 | D5W | 123 | 60 | 66.6 | 28 | 10 | 18 |
| 29 | 84 | Male | 2 | 117 | 100 | 46.7 | 60 | D5W | 118 | 100 | 30.8 | 74 | 8 | 10 |
| 30 | 78 | Female | 2 | 107 | 230 | 37.2 | 150 | DDAVP, D5W | 112 | 41 | 38.9 | 27 | 8 | 13 |
| Median | 71 | 3 | 119 | 230 | 30.2 | 187 | 118 | 70 | 43.8 | 30 | 8 | 12 | ||
| IQR | 54–83 | 2–4 | 116–122 | 119–372 | 15.4–36.8 | 88–317 | 114–122 | 44–103 | 31.9–89.5 | 10–67 | 6–9 | 9–15 | ||
D5W, dextrose 5% in water; DDAVP, desmopressin acetate; EFWC, electrolyte-free water clearance; IQR, interquartile range; NS, normal saline; s[Na], serum sodium concentration; u[Na+K], urinary sodium plus potassium concentration; UV, urine volume.